Latest news with #VAP
Business Standard
19-05-2025
- Business
- Business Standard
Dodla Dairy gains as Q4 PAT climbs 45% YoY to Rs 68 cr
Dodla Dairy added 3.43% after the dairy product maker reported 45.12% surge in consolidated net profit to Rs 67.96 crore on 15.51% jump in revenue from operations to Rs 909.62 crore in Q4 FY25 over Q4 FY24. Profit before tax (PBT) stood at Rs 90.28 crore in Q4 FY25, registering a growth of 40.75% from Rs 64.14 crore recorded in the corresponding quarter previous year. During the quarter, total expenses jumped 15.59% YoY to Rs 845.13 crore. The cost of materials consumed stood at Rs 613.32 crore (down 0.75% YoY) while employee benefit expenses was at Rs 40.61 crore (up 20.50% YoY) during the quarter. Value-Added Product sales for Q4 stood at Rs 284.10 crore, marking a 28.2% year-on-year growth. EBITDA jumped by 10.74% YoY to Rs 83.50 crore in the fourth quarter of FY25. EBITDA margin improved to 9.2% in Q4 FY25 as against 9.6% posted in Q4 FY24. Commenting on the performance, Managing Director of Dodla Dairy, Dodla Sunil Reddy said, I am pleased to share that during FY25, the companys PAT surpassed the Rs. 2,000 million milestone, reaching Rs 2,599 million, on the back of a topline of Rs 37,201 million, which grew at a healthy rate of 19%. This robust performance was primarily driven by faster growth in VAP and healthy performance in Africa as well as the Orgafeed business. Also, I would like to update you that the Board has approved dividend distribution of Rs 2 per share (20% of the face value). Our extensive procurement network and long-term relationships with the farmers underscore the underlying strength of our company. Over time, the company has built a strong leadership team, with dedicated General Managers heading each business vertical and reporting directly to the CEO of the company. Their contributions have been instrumental to our growth journey. We remain focused on advancing Dodla Dairys integrated business model through both organic and inorganic growth initiatives. With a continuous focus towards expanding our product reach and portfolio basket, we are confident to achieve accelerated growth in the coming years On a standalone basis, the companys net profit rallied 51.20% to Rs 56.70 crore on 10.97% rise in revenue from operations to Rs 807.87 crore in Q4 FY25 over Q4 FY24. On a full year basis, the companys consolidated net profit jumped 55.88% to Rs 259.93 crore on 19.02 rise in revenue from operations to Rs 3,720.1 crore in FY25 over FY24. Meanwhile, the companys board recommended a final dividend of Rs 2 per equity share of face value of Rs. 10 each for the financial year ended 31 March 2025, for the approval of members at the ensuing annual general meeting (AGM). The said final dividend, if approved by the shareholders, shall be paid/dispatched to the shareholders within 30 days from the date of declaration. The company has fixed 07 July 2025, as the record date for determining entitlement of members to receive the dividend for the financial year ended 31 March 2025. Further, the board of directors, based on the recommendations of the Nomination, Remuneration & Compensation Committee and the Audit Committee, has approved the re-appointment of Dodla Sunil Reddy as Managing Director of the company for a further term of five years, effective from 1 April 2026 to 31 March 2031. Dodla Dairy is a leading Indian dairy company. They procure, process, and sell a wide range of milk and milk products. With operations in multiple states, including international operations in Uganda and Kenya, Dodla Dairy has a strong distribution network of milk chilling centers, sales offices, agents, distributors, and retail parlors. Their diverse product portfolio includes milk, butter milk, ghee, curd, paneer, flavored milk, and more.
Economic Times
07-05-2025
- General
- Economic Times
VAPs, shoving peace down your throats
VAPs, shoving peace down your throats There's not many of them out in TV studios, or on social media. But somewhere in the tangled philosophies of non-violence and righteous indignation exists a rare but formidable breed: the violent, aggressive pacifist, or VAP. This person will lecture you on the virtue of peace, while jabbing a finger in your face for interrupting their soliloquy on 'An eye for an eye makes the whole world blind'. Fluent in the language of tranquillity, they wield it like a weapon, demanding that you embrace serenity or else.... VAPs don't simply oppose war - they wage battle against anyone who doesn't. Their pacifism is enforced with the intensity of a social media Manekshaw screaming orders at 'Like'- or '♥'-pressing troops. They insist on dialogue, but only if it consists of you nodding in agreement. Disagreement is considered an act of aggression. Should you foolishly express doubt, or an alternative perspective, be prepared to get pummelled for fuelling bloodlust. The hardcore VAP will threaten you - quite like the regular warmonger, from behind a screen, unless they're at loggerheads in front of a talking heads camera. They want a gentler world, for which they are willing to intimidate the pragmatic supporter of any military conflict resolution. If you ever meet one, just nod, smile and surrender. Resistance is futile, and deeply bellicose of you.
Korea Herald
01-04-2025
- Business
- Korea Herald
Hon Hai Technology Group (Foxconn) Completes Independent Audits At 9 More Manufacturing Sites
Demonstrating verified compliance with RBA VAP standards TAIPEI, April 1, 2025 /PRNewswire/ -- Hon Hai Technology Group ("Foxconn") (TWSE:2317) has completed independent, third-party audits of nine manufacturing campuses covering five countries, demonstrating, for a second year, a commitment to critical compliance and transparency in social and environmental responsibility by the world's largest electronics manufacturing service provider. No priority findings were assessed for the most part in the audits conducted under the Responsible Business Alliance Validated Assessment Program (RBA VAP), an industry standard that recognizes a factory's commitment to social and environmental responsibility and focuses on verified closure of issues identified in a VAP assessment. The audits covered Foxconn manufacturing sites in China, Vietnam, Malaysia, India and Mexico, showing an overall compliance rate of 89%. The Quang Chau campus in Vietnam's Bac Giang province was recognized at a Silver level under RBA VAP, outperforming the average score in the local industry. According to RBA, customers, investors, governments and other stakeholders consider the verified closure of audit findings critical to demonstrating compliance to their requirements. To enhance sustainability in Foxconn's operations and serve as a global best-practice model, the audits in 2024 also focused on campuses needing to strengthen third-party checks based on comprehensive assessment of their operational complexity, employee size, and past record in third-party audits. Audit areas covered labor rights, occupational health and safety, environment, ethics, supply chain management and interviews with 1,067 employees. Total scope included 210,000 employees and took the equivalent of 96 man-days. No priority findings were assessed, with the exception of one priority non-compliance in supply chain management due to overtime hours of an outsourced service provider, which has been addressed. The compliance rates for environment and ethics each reached over 97%, while those for labor, health and safety, and supply chain management each reached over 80%. Findings indicated a need to strengthen the management of the ratio of dispatched workers, overtime hours, calculation for social insurance and on-time severance payment, as well as attention to the on-site working environment in India. By end 2024, RBA VAP audits have been done at 58 sites with 8 recognized at Platinum level, 17 at Gold, and 20 at Silver. The first audits in 2023 covered eight sites in China and India.
Associated Press
14-03-2025
- Business
- Associated Press
Viromed Medical AG Reports Promising Study Results for PulmoPlas(R) in Intensive Care Unit Ventilator-Associated Pneumonia Patients
PINNEBERG, GERMANY / ACCESS Newswire / March 14, 2025 / Viromed Medical AG ('Viromed', Ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in room air sterilization, wound healing, and intensive care medicine, today announces promising study results for treating ventilator-associated pneumonia (VAP) in intensive care unit (ICU) patients using its cold atmospheric pressure plasma device candidate, PulmoPlas®. VAP is a severe lung infection caused by hospital-acquired germs in mechanically ventilated patients, with an estimated mortality rate of 10-13%. The study led by Prof. Hortense Slevogt, Hannover Medical School, and Helmholtz Centre for Infection Research, shows that the treatment with PulmoPlas® destroys bacteria in the upper and lower airways, including the hard-to-reach lower alveoli in 30 -90 seconds (in MRSA bacteria). The procedure is characterized by a high degree of tolerability, without any harmful effects on the respiratory epithelia (bronchial and alveolar). 'The results of our clinical trial have far exceeded our expectations in terms of efficacy and safety. Based on the available data, we are convinced that PulmoPlas® therapy will revolutionize pneumonia treatment worldwide,' said Uwe Perbandt, CEO of Viromed Medical AG. 'Our innovative procedure has the potential to save lives and significantly shorten hospital stays, and thus could benefit all hospitals with ICUs. As the only company in the world that can offer such a treatment, we are aware of our responsibility and will work vigorously to make PulmoPlas® available to hospitals as quickly as possible.' As part of the extensive review of the procedure, the positive safety results announced today regarding the use of PulmoPlas® will be validated via a second procedure. The detailed results of the clinical study are expected to be published in early summer 2025. Based on the study results, Viromed plans to submit an application to the Federal Institute for Drugs and Medical Devices (BfArM) for marketing authorization of PulmoPlas® as a medical device for the treatment of VAP. Since 2022, the Hannover Medical School, in cooperation with Viromed Medical AG, has been investigating the safety of cold plasma in bacterial infections of the respiratory tract using respiratory mucosa models. The work has been on the potential of cold plasma to kill bacteria that cause VAP. A second part of the clinical study (Project 2) with PulmoPlas® for the prevention of VAP is ongoing, with results expected in 2026. About Ventilator Associated Pneumonia and the use of cold plasma Ventilator Associated Pneumonia (VAP) is a frequent, avoidable and serious complication in mechanically ventilated patients. It occurs in patients who are invasively mechanically ventilated for at least 48 hours. Study results show that VAP occurs in 23-36% of mechanically ventilated patients, and is associated with prolonged ventilation time, longer stays in the intensive care unit and hospital, as well as increased cost. The estimated mortality rate is 10-13%. In Germany alone, there were around 486,000 mechanically ventilated intensive care patients in 2023 and many thousands of deaths, with a strong upward trend. Worldwide, many millions of patients are mechanically ventilated every year. Cold atmospheric plasma is an innovative physical, completely painless treatment method, that destroys viruses and bacteria in the respiratory tract in 30-90 seconds. Cold plasma is a groundbreaking innovation, particularly effective against antibiotic-resistant MRSA bacteria, as it destroys them. Antibiotics can take several hours or even days to reach the source of an infection, and are becoming increasingly ineffective due to the growing problem of multi-resistant germs. The use of cold plasma against VAP has the potential to reduce infections, accelerate healing, decrease antibiotic usage and, above all, save hundreds of thousands of lives every year. About Viromed Medical AG: Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of the innovative cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. In doing so, Viromed can draw on a broad customer base in the DACH region. Viromed Medical AG aims to further advance the use of CAP in medicine in the coming years and to realize corresponding growth potential. Contact Viromed Medical AG Uwe Perbandt Management Board Flensburger Straße 18 25421 Pinneberg Anne Hennecke / Dr. Kai Schmitz Phone: +49 (0) 211-529252-104
Chicago Tribune
03-03-2025
- Business
- Chicago Tribune
Judge dismisses lawsuit alleging violations in lucrative Illinois vendor program
A Cook County judge has dismissed a lawsuit alleging a company violated the terms of a lucrative state contract in ways that included failing to inform the state that a pair of political insiders profited from the deal. In a one-page order issued without commentary on Feb. 21, Judge Jerry Esrig dismissed the lawsuit with prejudice, meaning it can't be amended or refiled. The whistleblower lawsuit involved a state program started more than a decade ago that allowed certain contractors to buy up unpaid bills from the state, then collect the late fees. One of the companies that got in on the program was the Vendor Assistance Program owned by Brian Hynes, a longtime political insider. The lawsuit, filed by a Chicago attorney acting as a whistleblower for the state, alleged that Hynes' company and associated trusts purchased $5.7 billion in receivables through the state program but assigned many of them to 'a vast network of third parties' and granted 'profit participation rights to individuals never disclosed to the state.' An initial lawsuit was previously dismissed but the plaintiff last year filed an amended complaint that included allegations that former Democratic state Sen. James DeLeo and veteran Republican lobbyist Nancy Kimme were undisclosed recipients of profits from VAP's contract with the state. The amended complaint has now also been dismissed. In response to an earlier complaint and motion to dismiss, Esrig said all counts should be dismissed in part because the allegations were too similar to claims that had been publicly disclosed by outlets such as the news media, and that the plaintiff was not the original source of information presented in the suit. Michael Forde, the attorney whose firm filed the complaint and a former lawyer for former Mayor Rahm Emanuel, did not respond to requests for comment. A lawyer for the defendants, Benjamin Haskin, declined to comment on the dismissal Monday. The Vendor Assistance Program also became a major issue during the recent testimony of former Ald. Daniel Solis, who worked undercover for the FBI, in the corruption trial of former Illinois House Speaker Michael Madigan. Solis' sister, longtime Democratic operative Patti Solis Doyle, who co-founded VAP with Hynes, paid her brother more than half a million dollars over a period about about seven years, much of which was never reported on Solis' tax returns, according to testimony. What's more, Solis's sister was recorded by the FBI telling the alderman to 'revise' financial records in his tax filings and claim the $230,000 she'd paid him in 2016 as capital gains on a prior investment — which was not true. Solis acknowledged on the witness stand he'd done no work for VAP in return for the money. He also said he generally did not understand how taxes work and was acting on his sister's recommendations. 'Did you realize that your sister was recommending tax fraud?' Collins asked. 'No,' Solis said.
